 Practical Investment Analysis for the New Energy EconomyBig Pharma's iPhone Moment Is HereYou may have never heard of the Cray-1 supercomputer before, but after it was installed at Los Alamos National Laboratory back in 1976 — everything changed. This behemoth machine weighed five and a half tons, cost $8 million, and at the time was the most powerful computing machine on earth. Scientists used it to model nuclear weapons, weather patterns, and fluid dynamics… you can't get more state-of-the-art than that, folks. But by today's standards, the power of the Cray-1 is laughably underpowered. In fact, a single modern GPU outperforms it by a factor of thousands. Then Eli Lilly recently built one on 1,016 of those GPUs, with each one dedicated to a single purpose — discovering drugs faster than any laboratory in human history. It's called LillyPod and is the world's first NVIDIA DGX SuperPOD built with DGX B300 systems, powered by over 1,000 NVIDIA Blackwell Ultra GPUs. And it delivers more than 9,000 petaflops of AI performance. This game-changer for Big Pharma was assembled in just four months… and it went live this week in Indianapolis. But here's the number that stops me cold — the computational power that once required 7 million Cray supercomputers now fits inside a single NVIDIA GPU! And LillyPod has 1,016 of them. Think about that for a second. We're looking at the kind of category-defining leap that rewrites the rules of an entire industry before most people even realize the old rules are gone. And drug discovery? The old rules were brutal.
Your Window to Claim the Next "AI Equity Check" Is If you weren't already aware... AI firms have been caught "stealing" our personal data to train their AI models. And the U.S. government has decided to step in. This has led to the discovery of a brand-new passive income stream I call "AI Equity Checks." In short, AI firms are legally required to pay a handsome fee to a few special companies... Which then distribute these checks to everyday Americans like you. Right now regular folks are receiving as much as $3,452.50 per month (that's $41,430 every year for life). And you can too. It takes just five minutes to get set up before the next payout on March 31. Go here to get set up with "AI Equity Checks" before it's too late. The $2 Billion Lottery — And Why AI Just Bought the House Look, let's be honest about what traditional drug discovery actually was. Truth is, it's more akin to an educated lottery. Usually, scientists come up with a hypothesis, synthesize a compound, test it on cells, watch it fail, go back to the drawing board, then rinse and repeat — thousands of times — over a decade or more. That's why the average cost to bring a single drug to market is $2 billion. Of course, that's not to mention the average timeline it took these drugs to make it to market was between 10 to 15 years. And the success rate? 90% of drug candidates never even make it to a patient. But the problem with this drug development bottleneck was never really the science. The issue was pre physics… You see, a productive wet lab team can analyze roughly 2,000 molecular ideas per target per year — because every experiment requires physical synthesis and physical testing. So, you can only run so many experiments in a building with human hands and finite bench space. Today, LillyPod just eliminated that ceiling. In the dry lab — powered by AI — Lilly scientists can now test billions of molecular ideas at their fingertips — in parallel, in silico, before a single compound is ever synthesized. In other words, Eli Lilly just broke the wet lab and is helping to change the game forever. That's the mechanism most people are missing beneath the headline. But here's the catch… Eli Lilly isn't alone. Not even close. Sam Altman made headlines earlier this month at Cisco's AI Summit in San Francisco after suggesting that he's ready to invest in — or outright subsidize — pharmaceutical companies that use its AI models for drug discovery. Granted, his support will be in exchange for royalties on successful treatments. You can't help but wonder what it means when the CEO of the world's most powerful AI company starts eyeing-up drug royalties. Meanwhile, the clinical results are starting to arrive. Some of my readers remember that Insilico Medicine's Rentosertib — the first drug where both the target and the compound were discovered using generative AI — went from concept to human trials in under 18 months. Now, Insilico is posting positive Phase IIa results for idiopathic pulmonary fibrosis and is on a path toward pivotal trials. To put a little perspective on this, that same journey traditionally takes four to five years minimum… usually longer. The market is noticing. Global pharmaceutical investment in AI is projected to hit $2.51 billion in 2026 and balloon to $16.49 billion by 2034. There are now more than 200 AI-designed drug candidates in clinical development. Fifteen to twenty of them are entering pivotal trials this year alone. Don't get me wrong — this isn't a gold rush with a guaranteed pot at the end. Drug development is still inherently risky. We'll still see clinical failures happen — some already have — but here's the critical distinction: the question in 2026 is no longer whether AI can accelerate drug discovery. We know it can. The question now is which platforms — and which companies — will be the ones converting that acceleration into approved medicines. That's where things get interesting for us.
Big Pharma's iPhone Moment Is Here For us, this isn't just about Eli Lilly. Lillypod is the proof of concept — the billion-dollar signal flare that tells you which direction the industry is moving. When one of the oldest pharmaceutical companies on earth builds the world's most powerful private AI supercomputer and dedicates it entirely to drug discovery, you don't need to ask whether this trend is real. For us, we want to know who else is already inside it. You see, the market is still pricing AI drug discovery like it's a moonshot, perhaps something that'll pay off by 2030 if everything goes right. That's where the opportunity lives, dear reader, in the gap between what the market believes and what's actually happening in the lab right now. The smart money already knows this… Sam Altman is circling it, Eli Lilly is building infrastructure around it, and NVIDIA is supplying the picks and shovels. But a quiet layer of smaller, faster-moving AI drug platforms are already pushing novel candidates down the pipeline — without the billion-dollar overhead, or the legacy constraints, and certainly without Wall Street fully paying attention yet. That's the part most people miss. There's a familiar pattern in transformational technology. We see the infrastructure built out; the Cray-1 made headlines in 1976. Yet, the real fortune was made from those that took advantage of it. LillyPod already made headlines this week. Perhaps it's time you take a moment out of your day and check out the other hidden gem inside AI drug discovery — like this one right here. Until next time,
Keith Kohl A true insider in the technology and energy markets, Keith's research has helped everyday investors capitalize from the rapid adoption of new technology trends and energy transitions. Keith connects with hundreds of thousands of readers as the Managing Editor of Energy & Capital, as well as the investment director of Angel Publishing's Energy Investor and Technology and Opportunity. For nearly two decades, Keith has been providing in-depth coverage of the hottest investment trends before they go mainstream — from the shale oil and gas boom in the United States to the red-hot EV revolution currently underway. Keith and his readers have banked hundreds of winning trades on the 5G rollout and on key advancements in robotics and AI technology. Keith's keen trading acumen and investment research also extend all the way into the complex biotech sector, where he and his readers take advantage of the newest and most groundbreaking medical therapies being developed by nearly 1,000 biotech companies. His network includes hundreds of experts, from M.D.s and Ph.D.s to lab scientists grinding out the latest medical technology and treatments. You can join his vast investment community and target the most profitable biotech stocks in Keith's Topline Trader advisory newsletter.
|
Check us out on YouTube!
No comments:
Post a Comment